MAbSilico provide an AI-based software for the development of therapeutic antibodies, bio-drugs used in an increasing number of pathologies including oncology. These solutions substitute to the empirical and time-consuming techniques of preclinical antibody development (identification, characterization and optimization), leading to accelerated development times for the pre-clinical development phases of bio-drugs from several years to a few days.